NAFLD

This study looked at whether two different low-calorie Mediterranean diet plans, combined with moderate aerobic exercise, could improve liver health, gut function, and metabolic risk in 36 adults with obesity and non-alcoholic fatty liver disease (NAFLD). Participants followed on…

This pilot study tested whether ibutamoren, a drug that boosts growth hormone, can reduce fat buildup in the liver of people with nonalcoholic fatty liver disease (NAFLD). Twelve generally healthy adults with NAFLD took the drug for 6 months. Researchers measured changes in liver…

This study tested a new medicine called DD01 in 67 overweight or obese adults with a type of fatty liver disease (MASLD or MASH). The goal was to see if DD01 could safely reduce liver fat over 48 weeks compared to a placebo. Participants were randomly assigned to receive either D…

This study looked at 60 teenage girls with PCOS and obesity. They either took a weekly injection of semaglutide (a diabetes/weight-loss drug) or followed a special diet for 12 weeks. The goal was to see which approach better reduced liver fat and improved how the body uses insuli…

This study tested whether a combination of two drugs, dasatinib and quercetin, can reduce liver scarring in people with non-alcoholic fatty liver disease (NAFLD) and fibrosis. Thirty adults with biopsy-confirmed liver scarring took the drugs or a placebo for 21 weeks. The main go…

This study tested a new medicine called efinopegdutide in 381 adults with non-alcoholic steatohepatitis (NASH), a serious liver condition. The main goal was to see if the drug could stop signs of NASH without making liver scarring worse. Researchers also checked for side effects …

This study tested an experimental drug called elobixibat in 47 adults with nonalcoholic fatty liver disease (NAFLD) or its more severe form, NASH. The main goal was to see if the drug could lower bad cholesterol (LDL-C) compared to a placebo over 16 weeks. Researchers also monito…

This study looked at whether taking phytosterols (natural plant compounds) for 3 months could improve liver health, cholesterol, and insulin levels in 27 adults with nonalcoholic fatty liver disease (NAFLD). Participants took daily supplements while researchers tracked changes in…

This study looked at whether two blood tests, eLIFT and FibroMeter, can accurately detect advanced liver fibrosis (scarring) in people with type 2 diabetes. The researchers compared these blood tests to a liver scan (FibroScan) and, in some cases, a liver biopsy. The goal is to f…

This study tested a new way to perform MRI and MRE scans on children that doesn't require holding their breath. Standard scans can be hard for kids, especially those with liver disease. The researchers compared the new free-breathing method to the standard one in 135 children to …

This study looked at 1005 people with non-alcoholic fatty liver disease (NAFLD) to find better ways to check liver damage without using a needle biopsy. Researchers tested blood tests and special ultrasound devices to see how well they can spot serious liver scarring. The goal is…

This study looked at how well COVID-19 vaccines protect people with chronic liver disease, including hepatitis B, C, NAFLD, and NASH. Researchers followed 233 adults for 6 months, checking their immune response through blood tests and questionnaires. The goal was to see if liver …

This study looked at 292 people with non-alcoholic fatty liver disease (NAFLD) to see if the amount of scarring in the liver is linked to heart disease risk. Researchers used painless imaging tests to measure liver stiffness and coronary calcium, a marker of heart artery plaque. …

This study looked at the financial impact of non-alcoholic fatty liver disease (NAFLD) on 73 adults in Flanders, Belgium. Researchers used questionnaires to measure healthcare costs and patient expenses. The goal was to understand the economic burden of the disease, not to test a…

This study looked at how the hormone glucagon affects the liver's ability to break down proteins and fats. Researchers studied 21 people with obesity, type 2 diabetes, and fatty liver disease to understand if the body becomes resistant to glucagon. The goal was to learn more abou…